Who owns Prime Medicine, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PRME from SEC Form 13F filings across 187 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 187 institutions disclosed 106.6M shares of Prime Medicine, Inc. worth $393.5M — about 60.2% of shares outstanding; the largest disclosed holder is Alphabet Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
187
13F holders
$393.5M
value, 2026 filers
60.2%
of shares outstanding (106.6M sh)
24
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of PRME's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Alphabet Inc. | 16.6M | $61.1M | 0.1% | 9.3% | 0.0% |
| 2 | BlackRock, Inc. | 9.6M | $35.4M | 0.0% | 5.4% | +12.9% |
| 3 | ARK Investment Management LLC | 8.3M | $30.8M | 0.2% | 4.7% | +33.6% |
| 4 | STATE STREET CORP | 7.6M | $28.0M | 0.0% | 4.3% | +19.4% |
| 5 | T. Rowe Price Investment Management, Inc. | 5.2M | $19.3M | 0.0% | 3% | -4.5% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $16.7M | 0.0% | 2.6% | +1.1% |
| 7 | Balyasny Asset Management L.P. | 4.0M | $14.6M | 0.0% | 2.2% | -3.7% |
| 8 | GOLDMAN SACHS GROUP INC | 3.4M | $12.7M | 0.0% | 1.9% | +253.5% |
| 9 | Casdin Capital, LLC | 3.2M | $11.7M | 0.6% | 1.8% | 0.0% |
| 10 | Woodline Partners LP | 3.0M | $11.1M | 0.0% | 1.7% | 0.0% |
| 11 | UBS Group AG | 2.8M | $10.3M | 0.0% | 1.6% | -3.2% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 2.7M | $10.0M | 0.0% | 1.5% | -1.1% |
| 13 | Sumitomo Mitsui Trust Group, Inc. | 2.4M | $8.9M | 0.0% | 1.4% | -17.9% |
| 14 | Amova Asset Management Americas, Inc. | 2.4M | $8.9M | 0.1% | 1.4% | -18.2% |
| 15 | CITADEL ADVISORS LLC | 2.1M | $7.6M | 0.0% | 1.2% | +510.8% |
| 16 | ADAR1 Capital Management, LLC | 2.0M | $7.4M | 0.3% | 1.1% | +1.2% |
| 17 | FMR LLC | 1.8M | $6.5M | 0.0% | 1% | -0.4% |
| 18 | TWO SIGMA INVESTMENTS, LP | 1.5M | $5.6M | 0.0% | 0.9% | -3.1% |
| 19 | Redmile Group, LLC | 1.4M | $5.1M | 0.3% | 0.8% | -12.6% |
| 20 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 1.2M | $4.6M | 0.0% | 0.7% | 0.0% |
| 21 | Jump Financial, LLCNEW | 1.2M | $4.6M | 0.0% | 0.7% | new |
| 22 | BANK OF AMERICA CORP /DE/ | 981,335 | $3.6M | 0.0% | 0.6% | +70.1% |
| 23 | VANGUARD PORTFOLIO MANAGEMENT LLC | 961,826 | $3.5M | 0.0% | 0.5% | +11.6% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 927,538 | $3.4M | 0.0% | 0.5% | +1.1% |
| 25 | NORTHERN TRUST CORP | 912,597 | $3.4M | 0.0% | 0.5% | +2.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.